DK3351539T3 - Crystalline monohydrate complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(beta-d-glucopyranos-1-yl)-benzene and proline in crystal water (1:1:1), methods for its preparation and its use as an SGLT inhibitor - Google Patents
Crystalline monohydrate complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(beta-d-glucopyranos-1-yl)-benzene and proline in crystal water (1:1:1), methods for its preparation and its use as an SGLT inhibitor Download PDFInfo
- Publication number
- DK3351539T3 DK3351539T3 DK18155079.9T DK18155079T DK3351539T3 DK 3351539 T3 DK3351539 T3 DK 3351539T3 DK 18155079 T DK18155079 T DK 18155079T DK 3351539 T3 DK3351539 T3 DK 3351539T3
- Authority
- DK
- Denmark
- Prior art keywords
- glucopyranos
- proline
- cyclopropyl
- cyano
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177944 | 2012-07-26 | ||
| EP13740309.3A EP2877460B1 (en) | 2012-07-26 | 2013-07-25 | CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3351539T3 true DK3351539T3 (en) | 2023-01-30 |
Family
ID=48874313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18155079.9T DK3351539T3 (en) | 2012-07-26 | 2013-07-25 | Crystalline monohydrate complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(beta-d-glucopyranos-1-yl)-benzene and proline in crystal water (1:1:1), methods for its preparation and its use as an SGLT inhibitor |
| DK13740309.3T DK2877460T3 (en) | 2012-07-26 | 2013-07-25 | CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13740309.3T DK2877460T3 (en) | 2012-07-26 | 2013-07-25 | CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9145434B2 (en) |
| EP (3) | EP2877460B1 (en) |
| JP (2) | JP6538556B2 (en) |
| CN (2) | CN108774200A (en) |
| AR (1) | AR091908A1 (en) |
| AU (1) | AU2013294947B2 (en) |
| BR (1) | BR112015001327B1 (en) |
| CA (1) | CA2878698C (en) |
| DK (2) | DK3351539T3 (en) |
| EA (2) | EA025438B1 (en) |
| ES (2) | ES2937665T3 (en) |
| FI (1) | FI3351539T3 (en) |
| HR (2) | HRP20230081T1 (en) |
| HU (1) | HUE061450T2 (en) |
| LT (1) | LT3351539T (en) |
| MX (1) | MX357906B (en) |
| PL (2) | PL2877460T3 (en) |
| PT (2) | PT3351539T (en) |
| RS (1) | RS63881B1 (en) |
| SG (1) | SG11201500574QA (en) |
| SI (2) | SI2877460T1 (en) |
| TW (1) | TW201418275A (en) |
| WO (1) | WO2014016381A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| EP4245765A3 (en) | 2013-04-04 | 2024-03-20 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in equine animals |
| DK3082829T3 (en) | 2013-12-17 | 2021-05-03 | Boehringer Ingelheim Vetmedica Gmbh | SGLT2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS IN CATS |
| DK3096765T3 (en) | 2014-01-23 | 2019-03-04 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in dogs |
| ES2811261T3 (en) * | 2014-04-01 | 2021-03-11 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
| CN103965020B (en) * | 2014-05-06 | 2015-09-09 | 启东东岳药业有限公司 | Prepare the method for 5-iodo-2-bromobenzyl alcohol |
| WO2016046150A1 (en) * | 2014-09-25 | 2016-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| BR112017005454A2 (en) * | 2014-09-30 | 2017-12-12 | Jiangsu Hengrui Medicine Co | sodium glucose transporter inhibitor 2 l-proline compound, and l-proline compound monohydrate and crystal |
| CZ2015110A3 (en) * | 2015-02-18 | 2016-08-31 | Zentiva, K.S. | Empagliflozin solid forms |
| AU2016310535B2 (en) | 2015-08-27 | 2021-08-19 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising SGLT-2 inhibitors |
| WO2017203457A1 (en) * | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Solid state forms of empagliflozin |
| JP6785523B2 (en) * | 2016-05-28 | 2020-11-18 | ジ・リン・フイ・シェン・バイオ−ファーマシューティカル・カンパニー・リミテッドＪｉ Ｌｉｎ Ｈｕｉ Ｓｈｅｎｇ Ｂｉｏ−Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Crystal form of sodium-glucose cotransporter 2 inhibitor |
| EA202091466A1 (en) | 2017-12-19 | 2020-10-23 | Бёрингер Ингельхайм Ветмедика Гмбх | SYNTHESIS OF SOCRYSTAL 1: 1: 1 1-CIANO-2- (4-CYCLOPROPYLBENZYL) -4 - (- D-GLUCOPYRANOSE-1-YL) BENZENE, L-PROLINE AND WATER |
| BR112022010385A2 (en) | 2019-11-28 | 2022-08-23 | Boehringer Ingelheim Vetmedica Gmbh | USE OF SGLT-2 INHIBITORS IN THE DRYING OF NON-HUMAN MAMMALS |
| EP4106744A1 (en) | 2020-02-17 | 2022-12-28 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
| KR20240041966A (en) | 2021-07-28 | 2024-04-01 | 베링거잉겔하임베트메디카게엠베하 | Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac disease in non-human mammals other than cats, especially dogs |
| CN117715639A (en) | 2021-07-28 | 2024-03-15 | 勃林格殷格翰动物保健有限公司 | Use of SGLT-2 inhibitors for the prevention and/or treatment of kidney disease in non-human mammals |
| EP4376819A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| WO2023227492A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1385856B1 (en) * | 2001-04-11 | 2006-02-22 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| EP1581543A4 (en) * | 2003-01-03 | 2008-03-19 | Bristol Myers Squibb Co | Methods of producing c-aryl glucoside sglt2 inhibitors |
| SG151271A1 (en) * | 2004-03-16 | 2009-04-30 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
| JP5345846B2 (en) * | 2005-09-08 | 2013-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Crystal form of 1-chloro-4- (β-D-glucopyranos-1-yl) -2- (4-ethynyl-benzyl) -benzene, process for its preparation and their use for the manufacture of a medicament |
| EP1989191B1 (en) | 2006-02-15 | 2011-07-20 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| PE20080697A1 (en) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| AR065809A1 (en) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR |
| CN101754972A (en) * | 2007-05-18 | 2010-06-23 | 百时美施贵宝公司 | Crystalline structure of SGLT2 inhibitor and preparation method thereof |
| CN103319445B (en) * | 2007-12-27 | 2016-01-20 | 阿斯利康公司 | Crystalline structure of SGLT2 inhibitor and preparation method thereof |
| PL2324002T3 (en) * | 2008-08-22 | 2017-03-31 | Theracos Sub, Llc | Processes for the preparation of sglt2 inhibitors |
| PE20110288A1 (en) | 2008-08-28 | 2011-05-26 | Pfizer | DIOXA-BICYCLE DERIVATIVES [3.2.1] OCTANE-2,3,4-TRIOL |
| US20100167988A1 (en) | 2008-10-22 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Ethoxyphenylmethyl inhibitors of sglt2 |
| WO2011153712A1 (en) * | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| EP4245765A3 (en) | 2013-04-04 | 2024-03-20 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in equine animals |
-
2013
- 2013-07-23 US US13/948,751 patent/US9145434B2/en active Active
- 2013-07-25 BR BR112015001327-9A patent/BR112015001327B1/en active IP Right Grant
- 2013-07-25 DK DK18155079.9T patent/DK3351539T3/en active
- 2013-07-25 MX MX2015000962A patent/MX357906B/en active IP Right Grant
- 2013-07-25 EA EA201500038A patent/EA025438B1/en not_active IP Right Cessation
- 2013-07-25 ES ES18155079T patent/ES2937665T3/en active Active
- 2013-07-25 SI SI201331237T patent/SI2877460T1/en unknown
- 2013-07-25 PT PT181550799T patent/PT3351539T/en unknown
- 2013-07-25 LT LTEP18155079.9T patent/LT3351539T/en unknown
- 2013-07-25 SI SI201332031T patent/SI3351539T1/en unknown
- 2013-07-25 EP EP13740309.3A patent/EP2877460B1/en active Active
- 2013-07-25 EP EP22202153.7A patent/EP4166548A1/en active Pending
- 2013-07-25 EP EP18155079.9A patent/EP3351539B1/en active Active
- 2013-07-25 HU HUE18155079A patent/HUE061450T2/en unknown
- 2013-07-25 DK DK13740309.3T patent/DK2877460T3/en active
- 2013-07-25 PL PL13740309T patent/PL2877460T3/en unknown
- 2013-07-25 PL PL18155079.9T patent/PL3351539T3/en unknown
- 2013-07-25 CN CN201810468431.9A patent/CN108774200A/en active Pending
- 2013-07-25 AU AU2013294947A patent/AU2013294947B2/en active Active
- 2013-07-25 CN CN201380037186.1A patent/CN104470908A/en active Pending
- 2013-07-25 RS RS20230025A patent/RS63881B1/en unknown
- 2013-07-25 HR HRP20230081TT patent/HRP20230081T1/en unknown
- 2013-07-25 ES ES13740309.3T patent/ES2694675T3/en active Active
- 2013-07-25 EA EA201600506A patent/EA201600506A1/en unknown
- 2013-07-25 WO PCT/EP2013/065736 patent/WO2014016381A1/en active Application Filing
- 2013-07-25 PT PT13740309T patent/PT2877460T/en unknown
- 2013-07-25 CA CA2878698A patent/CA2878698C/en active Active
- 2013-07-25 JP JP2015523552A patent/JP6538556B2/en active Active
- 2013-07-25 TW TW102126724A patent/TW201418275A/en unknown
- 2013-07-25 AR ARP130102660A patent/AR091908A1/en unknown
- 2013-07-25 SG SG11201500574QA patent/SG11201500574QA/en unknown
-
2018
- 2018-05-08 JP JP2018089968A patent/JP2018135384A/en active Pending
- 2018-11-23 HR HRP20181972TT patent/HRP20181972T1/en unknown
-
2022
- 2022-07-25 FI FIEP18155079.9T patent/FI3351539T3/en active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3351539T3 (en) | Crystalline monohydrate complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(beta-d-glucopyranos-1-yl)-benzene and proline in crystal water (1:1:1), methods for its preparation and its use as an SGLT inhibitor | |
| NO2020024I1 (en) | Combination of relebactam, optionally in the form of monohydrate, imipenem and cilastatin, optionally in the form of sodium salt | |
| DK2455374T3 (en) | Process for the preparation of compounds that can be used as inhibitors of SGLT | |
| NO2018019I2 (en) | Ertugliflozin, optionally as a crystal form, especially as a co-crystal with L-pyroglutamic acid, and especially as Ertugliflozin L-pyroglutamic acid | |
| DK2751102T3 (en) | Compounds and Compositions as C-kit Kinase Inhibitors | |
| CL2014001628A1 (en) | Methods for purifying ateviol glycosides; compositions and uses thereof | |
| DK2920149T3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS ROR-GAMMA T INHIBITORS AND USES THEREOF | |
| ZA201404273B (en) | 2',4'-diflouro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| EP3110901A4 (en) | Use of r-1233 in liquid chillers | |
| CL2012002737A1 (en) | Humanized anti-cd40 antibody; polynucleotide encoding it; pharmaceutical composition comprising said antibody; and its use to block an immune response mediated by human cd40. | |
| CL2014002903A1 (en) | Geopolymeric composition of aluminosilicate; Preparation method and its uses. | |
| DK2877574T3 (en) | ALPHA (1,2) -FUCOSYL TRANSFERASES SUITABLE FOR USE IN THE PREPARATION OF FUCOSYLATED OLIGOSACCHARIDES | |
| DK2475372T4 (en) | Method for the preparation of micro-RNA and its therapeutic use | |
| DK2272339T3 (en) | Methods and compositions for use with gel dispensers | |
| DK3141542T3 (en) | Substituted benzaldehyde compounds and methods for their use in increasing tissue siltation | |
| DK3424920T3 (en) | CO CRYSTALS OF (S) -N-METHYL-8- (1 - ((2'-METHYL- [4,5'-BIPYRIMIDIN] -6-YL) AMINO) PROPAN-2-YL) QUINOLIN-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS | |
| EP2757139A4 (en) | Compound, liquid crystal composition and liquid crystal display element | |
| EP2502973A4 (en) | Liquid crystal composition comprising polymerizable compound, and liquid crystal display element using said liquid crystal composition | |
| PL2798398T3 (en) | Multiple glazing having variable diffusion by liquid crystals | |
| DK2736888T3 (en) | 3-HETEROAROYLAMINOPROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | |
| DK2665793T3 (en) | AZEOTROPLAN COMPOSITIONS OF TRANS-1,1,1,4,4,4-HEXAFLUOR-2-BUTEN AND WATER | |
| DK1994005T3 (en) | Tetrahydronaphthalene derivatives, process for their preparation and use as inflammatory inhibitors | |
| DK2930148T3 (en) | SAPO-34-ZEOLITE WITH DIGLYCOLAMINE AS TEMPLATE AND PROCEDURE FOR SYNTHESIS OF ZEOLITE | |
| DK2683371T3 (en) | COMPOUNDS AND METHODS FOR IMPROVING THE DETERIORED ENDOGEN FIBRINOLYSE USING HISTONDEACETYLASE INHIBITORS | |
| DK2621517T4 (en) | COMPOSITION FOR USE IN THE TREATMENT OF INFERTILITY |